spacer
home > pmps > autumn 2003 > who nose how far nasal delivery can go?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Who Nose How Far Nasal Delivery Can Go?

Nasal delivery has traditionally been restricted to topically acting substances used to treat the common cold and nasal allergies. Recently however, there has been increased interest in the nose as an alternative to oral delivery and injection for many systemic drugs and vaccines. The highly vascularised and immunogenic nasal mucosa offers potential advantages in terms of quick action, improved bio-availability and patient compliance as well as improved immune response for vaccines.

Faced with surging drug development costs and fierce generic competition, pharmaceutical companies are under increasing pressure to find ways to increase and prolong the profitability of both existing and new products. In addition, many of the advanced molecules being developed by biotechnology companies require more efficient delivery than that offered by conventional delivery routes and systems. The challenge of optimising the bio-availability and patient compliance of these expensive molecules are other significant drivers for the development of novel drug delivery systems. If successful, reformulation allied with novel delivery systems provide powerful tools for improving efficiency and differentiating a product from those of competitors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Per Gisle Djupesland, Head of R&D and Co-Founder of OptiNose AS

Dr Per Gisle Djupesland is Co-Founder, Head of R&D and Chairman of OptiNose AS, a Norwegian R&D company developing a novel concept for nasal delivery of drugs and vaccines. He is a specialist in Otorhinolaryngology with a PhD in Nasal Physiology from the University of Oslo and has been Research Fellow at the University of Toronto, Canada. He has a degree in International Health and Tropical Medicine from Paris, France, and has been Project Manager for a large-scale vaccination trial in the Norwegian Armed Forces.

spacer
Dr Per Gisle Djupesland
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Entry now open for the PPMA Group Industry Awards 2019

The 2019 PPMA Group Industry Awards will be held at the National Conference Centre (NEC), Birmingham, on the evening of the first day of the PPMA Total Show 2019 – Tuesday, 1 October 2019. 
More info >>

White Papers

High Potency Drugs – from Molecule to Market

PCI Pharma Services

PCI Pharma Services has invested in state-of-the-art containment equipment and created a ‘Potent Passport’ philosophy to identify the specific handling requirements for any Highly Potent Active Pharmaceutical Ingredients (HPAPI) project. Backed by 30 years’ experience of managing potent molecules, PCI Pharma Services is the logical choice when selecting an outsourcing partner.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement